Board of Health — Skokie, IL
Date: 2024-05-09

Skokie Board of Health
 Thursday, May 9, 2024
 7:00 pm
 Conference Room D&E, Village Hall, 5127 Oakton St

 AGENDA

I. Call to Order

II. Approval of Agenda

III. Approval of Minutes: April 11, 2024 Meeting

IV. Old Business
 A. Niles Township School District 219 Presentation/Discussion – Youth
 Mental Health – Fall of 2024

V. Guest Speaker: Jerrold B. Leikin MD, Cannabinoids and Health

VI. Public Comments

VII. Adjournment

 Next Regular Meeting: June 13, 2024 @ 7:00 p.m.




Doc#: 618781, Version:1

Skokie Board of Health
 Thursday, May 9, 2024
 7:00 pm
 Conference Room D&E, Village Hall, 5127 Oakton St


 MINUTES

In attendance: Dr. Swapna Dave, Dr. Bruce Gaynes, Dr. Michael Gottesman, Maureen Hanlon,
Margaret Keeler, Dr. Girijia Kalyan Kumar, Dr. Edward Linn (Chair), Dr. Kyungran Shim, Dr. Romil
Sood, Patricia Urbanus, Irtaza Usman, Rohit Pandya, Ruth Varma, Dr. William Werner, Dr. Larry
Williams, Sibyl Yau; Trustee James Johnson; Staff Liaison: Mike Charley
Not in attendance: Juliet Haido, Heidi Nickisch Duggan, Jan Shiffman, Trustee Keith Robinson

I. Call to Order @ 7:03 PM

II. Approval of Agenda: First by Dr. Williams, Second by Sood, Approved

III. Approval of Minutes: April 11, 2024 Meeting: First by Dr. Williams, Second by Sood,
 Approved

IV. Old Business
 A. Niles Township School District 219 Presentation/Discussion – Youth Mental
 Health – Fall of 2024: Mike Charley communicated that since the last BOH
 meeting (April 11, 2024) he had successfully touched base with Bridget Connolly,
 Assistant Superintendent Special Education & Student Services at School District
 219 via email. Bridget communicated that she would be willing to present to the
 BOH in the fall of 2024 regarding information on District 219’s insights and
 experiences with youth mental health.

V. Guest Speaker: Jerrold B. Leikin MD, Cannabinoids and Health: Dr. Leikin was invited to
 share his expertise on cannabinoids and their impact on health. His presentation
 covered various aspects of cannabis, including its different types, case studies, health
 data, and a medical toxicology perspective. He highlighted the correlation between the
 legalization of recreational cannabis and negative health outcomes, noting an increase
 in such outcomes in states where recreational cannabis is legal.

 Dr. Leikin pointed out the significant rise in recreational cannabis sales since legalization,
 with expectations of continued growth. He emphasized the increasing potency of THC
 levels in cannabis products and raised concerns about the lack of quality control in their
 manufacturing. He advocated for stringent quality control measures to ensure product
 safety and better consumer reassurance. He also criticized current cannabis product
 labeling as inadequate and called for improved transparency.

Doc#: 619532, Version:1
 Dr. Leikin reported a rise in marijuana toxicity cases, which are increasingly seen in
 emergency departments, critical care units, psychiatric facilities, and reflected in the
 growing number of poison center calls. He expressed his opposition to cannabis
 legalization, citing several reasons: unpredictable pharmacology, rising adolescent use,
 insufficient patient education, increased poison center calls, potentially unlimited THC
 doses, adverse pregnancy effects, growing synthetic cannabis use, inadequate labeling
 standards, and the unclear benefits of cannabis.

 Dr. Leikin recommended that public health authorities take an active role in this issue.
 He urged them to acknowledge the lack of public health benefits from recreational
 cannabis use, advocate for standardized labeling, ensure public education, discourage
 smoking and vaping, and push for quality control in cannabis product manufacturing.

VI. Public Comments: None

VII. Adjournment at 8:30 PM

 Next Regular Meeting: June 13, 2024 @ 7:00 p.m.




Doc#: 619532, Version:1